24 November 2020: Original Paper
Role of Renal Replacement Therapy During the Peri-Transplant Period of Heart Transplantation
Sua Lee 1ABCDEF , Tae Hyun Ban 2ABCDEF* , Hoon Suk Park 2BF , Suk Min Seo 3EF , Byung Ha Chung 45CF , Jihyang Lim 6EF , Eun-Jee Oh 7BC , Bumsoon Choi 2EF , Cheol Whee Park 4EF , Chul Woo Yang 45CDE , Sang Hong Baek 8DE , Yong-Soo Kim 4EFDOI: 10.12659/AOT.925648
Ann Transplant 2020; 25:e925648
Table 1 Patients’ basic demographics.
| Variable | Non-AKI (n=6) | AKI | P value | ||
|---|---|---|---|---|---|
| Total (N=15) | Non-RRT (n=5) | RRT (n=10) | |||
| Age (years), mean±SD | 40.3±10.9 | 44.6±16.0 | 43.4±17.8 | 45.2±16.0 | 0.499 |
| Sex, Male, n (%) | 6 (100) | 12 (75.0) | 4 (80.0) | 8 (80.0) | 0.497 |
| Type of heart transplantation, n (%) | 0.504 | ||||
| Emergent | 4 (66.7) | 6 (40.0) | 2 (40.0) | 4 (40.0) | |
| Urgent | 2 (33.3) | 7 (46.7) | 3 (60.0) | 4 (40.0) | |
| Elective | 0 | 2 (13.3) | 0 | 2 (20.0) | |
| Follow-up duration (months), median (IQR) | 104.5 (4.7, 117.7) | 11.5 (5.9, 35.7) | 16.0 (6.6, 47.6) | 10.4 (3.3, 36.9) | 0.263 |
| Comorbidity | 0.433 | ||||
| HTN, n (%) | 1 (16.7) | 3 (20.0) | 1 (20.0) | 2 (20.0) | |
| DM, n (%) | 2 (33.3) | 6 (40.0) | 1 (20.0) | 5 (50.0) | |
| CAD, n (%) | 2 (33.3) | 8 (53.3) | 4 (80.0) | 4 (40.0) | |
| MI, n (%) | 2 (33.3) | 6 (40.0) | 3 (60.0) | 3 (30.0) | |
| Underlying cardiac disease, n (%) | 0.335 | ||||
| DCMP | 4 (66.7) | 7 (46.7) | 1 (20.0) | 6 (60.0) | |
| ICMP | 2 (33.3) | 7 (46.7) | 4 (80.0) | 3 (30.0) | |
| Other | 0 | 1 (6.7) | 0 (0.0) | 1 (10.0) | |
| Cardiac ischemic time (min), median (IQR) | 114.0 (83.0, 145.0) | 133.0 (110.5, 193.0) | 145.0 (126.0, 284.0) | 111.0 (87.0, 240.0) | 0.373 |
| LVEF at time of admission (%), mean±SD | 29.3±10.1 | 18.6±7.1 | 19.5±5.0 | 18.2±8.2 | ** |
| Baseline serum Cr (mg/dL), mean±SD | 0.8±0.2 | 1.2±0.6 | 0.9±0.3 | 1.4±0.6 | ** |
| Baseline CKD-EPI eGFR (mL/min/1.73 m), mean±SD | 113.1±17.3 | 78.2±32.5 | 96.3±30.0 | 69.1±31.2 | ** |
| Serum Cr on 1 day before HT (mg/dL), median (IQR) | 0.8 (0.4,0.9) | 1.7 (1.3,2.0)* | 1.6 (1.3,2.3) | 1.9 (1.3,2.1)* | ** |
| CKD-EPI eGFR on 1 day before HT (mL/min/1.73 m), median (IQR) | 113.8 (99.7,142.4) | 43.6 (36.1,59.7)* | 56.5 (33.8,65.3) | 41.1 (33.7,61.9)* | ** |
| Induction IST, n (%) | 0.186 | ||||
| Basiliximab | 6 (100) | 9 (60.0) | 3 (60.0) | 6 (60.0) | |
| ATG | 0 | 6 (40.0) | 2 (40.0) | 4 (40.0) | |
| Maintenance IST, n (%) | 0.856 | ||||
| Tacrolimus | 5 (83.3) | 13 (86.7) | 4 (80.0) | 9 (90.0) | |
| Cyclosporine | 1 (16.7) | 2 (13.3) | 1 (20.0) | 1 (10.0) | |
| Steroid | 2 (33.3) | 9 (60.0) | 4 (80.0) | 5 (50.0) | |
| Mycophenolate mofetil | 6 (100.0) | 15 (100.0) | 5 (100.0) | 10 (100.0) | |
| Everolimus | 1 (16.7) | 1 (6.7) | 0 (0.0) | 1 (10.0) | |
| ATG – anti-thymoglobulin; CAD – coronary artery disease; CKD-EPI eGFR – chronic kidney disease epidemiology collaboration estimated glomerular filtration rate; Cr – creatinine; DCMP – delayed cardiomyopathy; DM – diabetes mellitus; HTN – hypertension; ICMP – ischemic cardiomyopathy; IQR – interquartile range; IST – immunosuppressant; LVEF – left ventricular ejection fraction; MI – myocardial infarction; RRT – renal replacement therapy, SD – standard deviation. * If the patient required RRT, serum Cr and CKD-EPI eGFR were assessed immediately prior to RRT initiation; ** p *** p | |||||